YKST02

DRUG4 trials

Sponsors

Excyte Biopharma Ltd, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

Primary IgA NephropathyRelapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple Myeloma (RRMM)System Lupus Erythematosus(SLE)

Early Phase 1

A Study of YKST02 in Participants With Primary IgA Nephropathy

RecruitingNCT07498673

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyPrimary IgA Nephropathy

Start: 2026-05-06End: 2027-06-30Target: 12Updated: 2026-05-12

Phase 1

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

RecruitingNCT06574568

Excyte Biopharma LtdRelapsed or Refractory Multiple Myeloma

Start: 2024-06-14End: 2027-06-30Target: 70Updated: 2026-02-05

Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus

Not yet recruitingNCT07512947

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySystem Lupus Erythematosus(SLE)

Start: 2026-05-01End: 2028-06-30Target: 30Updated: 2026-04-06

Phase 2

Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

Not yet recruitingNCT07695740

Excyte Biopharma LtdRelapsed or Refractory Multiple Myeloma (RRMM)

Start: 2026-09-01End: 2029-09-01Target: 64Updated: 2026-07-10